Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REC-7735 in PIK3CA-H1047R Mutated Solid Tumors
NCT07819136Phase 2Recruiting
- Sponsor
- Recursion Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- Jan 2031
- Countries
- 1
01
Overview
A Phase 2 trial of REC-7735 in solid tumor, sponsored by Recursion Pharmaceuticals. Started Sep 2026; status: recruiting.
02
Drugs
REC-7735
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07819136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07819136.